Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Upsher-Smith To Buy U.K. Biotech Partner Proximagen For $347 Million

This article was originally published in The Pink Sheet Daily

Executive Summary

Proposed acquisition mimics other recent M&A deals, like Sanofi/Genzyme, with inclusion of contingent-value rights pegged to success of two clinical candidates.

You may also be interested in...



Finland's Biotie Therapies Renegotiates Nalmefene Deal And Receives €30 Million Funding Lifeline

With the end of its cash runway on the horizon, Finland’s Biotie Therapies has received an equity investment of €10 million from Lundbeck and €20 million from institutional investors, after renegotiating the ex-Europe part of its worldwide nalmefene licensing pact.

Deals Of The Week: Upsher-Smith/Proximagen, Novo Nordisk/JDRF, Newron/NeuroNova

With BIO 2012 taking place June 17-21, the entire health care world awaits the Supreme Court’s ruling on health care reform. In the pharma world, companies are strategizing against all the possible outcomes.

Specialty Pharma Dominates Epilepsy Market, But Does It Have Resources To Develop Disease-Modifying Agents?

Upsher-Smith’s recent acquisition of research boutique Proximagen highlights the dynamics of the market: specialty pharma extending dominance and introducing new agents to the market, while most early R&D activity originates at small firms. But it may be difficult for this combination of players to bring forth the game-changing therapies that are needed, given the technical challenges of the disease space.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel